PMU55 - CONSEQUENCES ON ECONOMIC OUTCOMES OF GENERIC VERSUS BRAND-NAME DRUGS USED IN ROUTINE CLINICAL PRACTICE- THE CASE OF TREATING PERIPHERAL NEUROPATHIC PAIN OR GENERALIZED ANXIETY DISORDER WITH PREGABALIN
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1891
https://www.valueinhealthjournal.com/article/S1098-3015(18)35193-3/fulltext
Title :
PMU55 - CONSEQUENCES ON ECONOMIC OUTCOMES OF GENERIC VERSUS BRAND-NAME DRUGS USED IN ROUTINE CLINICAL PRACTICE- THE CASE OF TREATING PERIPHERAL NEUROPATHIC PAIN OR GENERALIZED ANXIETY DISORDER WITH PREGABALIN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35193-3&doi=10.1016/j.jval.2018.09.1891
First page :
Section Title :
Open access? :
No
Section Order :
1256